SCHEMBL2909313

SCHEMBL2909313

O=C(C=CN1CCN(Cc2cccc(F)c2)CC1)c1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.52
NPY2R P49146 1/20 0.48
GPR183 P32249 1/20 0.47
ALDH1A1 P00352 4/20 0.47
TSHR P16473 2/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SIGMAR1 Q99720 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.45
F2R P25116 1/20 0.45
ALDH3A1 P30838 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906083 0.89 SIGMAR1 (0.57) FAAHALDH1A1TSHRKDM4ESMN1; SMN2
SCHEMBL2905103 0.89 F2R (0.57) FAAHGPR183KMT2AMEN1F2R
SCHEMBL2905713 0.87 ALDH1A1 (0.46) FAAHALDH1A1TSHRKDM4ESMN1; SMN2
SCHEMBL2907155 0.87 ALDH1A1 (0.56) FAAHALDH1A1KDM4ECYP2D6CYP2C9
SCHEMBL2903101 0.83 SIGMAR1 (0.51) FAAHGPR183SIGMAR1KMT2AMEN1
SCHEMBL2904068 0.81 LMNA (0.51) FAAHALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL2906184 0.81 ALDH1A1 (0.54) FAAHNPY2RGPR183ALDH1A1KDM4E
SCHEMBL2901992 0.80 KMT2A (0.46) FAAHNPY2RGPR183ALDH1A1KDM4E
SCHEMBL2905724 0.80 FAAH (0.53) FAAHALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL2903083 0.79 HTR2A (0.46) F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PEREZ MICHEL (FR) 2012-09-13 US claimed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP claimed
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2009-07-09 US claimed
EP-2041104-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS Pierre Fabre Medicament (FR) 2009-04-01 EP claimed
WO-2007147824-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2007-12-27 WO claimed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 FAAH 506/4885NPY2R 539/4885GPR183 891/4885
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 FAAH 506/4885NPY2R 539/4885GPR183 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.